drugset
Drugs / recombinant human luteinizing hormone
last change Feb 2021 re-read 9 days ago

recombinant human luteinizing hormone

also known as rhLH

Protein / enzyme biologic

Developed for
infertility disorder
Investigated by
Fundacion Dexeus · Merck, S.L., Spain

Trials 1

today NCT04719000 · Ph 4
2021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 4 NCT04719000 Feb 2021 → Aug 2027 expected infertility disorder Fundacion Dexeus Recruiting No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as recombinant human luteinizing hormone “150 IU recombinant human luteinizing hormone (rhLH) in a gonadotropin-releasing hormone (GnRH) antagonist protocol.” NCT04719000 ↗
Known as rhLH ClinicalTrials.gov intervention name — accepted as the source's own label NCT04719000 ↗
Modality Protein / enzyme biologic “150 IU recombinant human luteinizing hormone (rhLH) in a gonadotropin-releasing hormone (GnRH) antagonist protocol.” NCT04719000 ↗